{
    "response": "Based on your clinical data and current medical understanding, I can provide you with comprehensive information about the long-term prognosis for your left eye primary acute angle-closure glaucoma.\n\n**Direct Answer to Your Question**\nThe long-term prognosis for your left eye depends primarily on how effectively we can prevent future acute attacks and control your intraocular pressure. With proper treatment and monitoring, many patients maintain good vision, but there are significant risks if the condition is not well-managed.\n\n**Your Specific Clinical Context**\nYou experienced a significant acute angle-closure attack in your left eye with symptoms including severe pain, blurred vision, eye redness, and elevated intraocular pressure (noted as T+2). Your examination showed corneal edema, shallow anterior chamber, and lens turbidity. This acute episode represents a critical event that requires immediate and ongoing management to prevent permanent damage.\n\n**Key Long-Term Prognosis Considerations**\n\n1. **Risk of Optic Nerve Damage**: The most serious long-term concern is the development of glaucomatous optic neuropathy. Each acute angle-closure episode causes damage to the optic nerve head and retinal nerve fiber layer. Even if individual attacks are treated successfully, repeated episodes lead to cumulative damage that can result in permanent vision loss.\n\n2. **Prevention of Future Attacks**: Your long-term prognosis improves significantly with preventive measures. Laser peripheral iridotomy (LPI) is typically recommended to create a small opening in your iris, allowing aqueous humor to flow more freely and reducing the risk of future angle-closure episodes.\n\n3. **Monitoring Requirements**: You will need regular monitoring of your intraocular pressure, optic nerve head, and retinal nerve fiber layer. This includes IOP measurements, gonioscopy (to examine your eye's drainage angle), and structural evaluations to detect any progression of damage.\n\n4. **Potential for Chronic Glaucoma**: There's a risk that your acute angle-closure could progress to chronic primary angle-closure glaucoma (PACG), especially if peripheral anterior synechiae (permanent adhesions between iris and cornea) develop. This represents a transition to a more chronic condition requiring ongoing management.\n\n**Factors Influencing Your Prognosis**\n\n- **Demographic Factors**: As a 79-year-old female, you have demographic characteristics that align with higher risk profiles for angle-closure glaucoma.\n- **Treatment Response**: How well you respond to medical therapy (eye drops to lower pressure) and any surgical interventions will significantly impact your long-term outcomes.\n- **Adherence to Monitoring**: Regular follow-up appointments are crucial for detecting progression and adjusting treatment as needed.\n\n**What You Can Expect**\n\nWith appropriate management, the goals are to:\n- Prevent further acute attacks\n- Control your intraocular pressure to target levels\n- Preserve your existing visual function\n- Maintain your quality of life\n\nYou will likely need ongoing medical therapy with pressure-lowering eye drops, and possibly surgical intervention if medical therapy alone is insufficient. Regular visual field testing and imaging studies will be necessary to monitor for any progression of optic nerve damage.\n\n**Important Next Steps**\n1. Complete any recommended laser or surgical procedures to prevent future acute attacks\n2. Adhere strictly to prescribed medication regimens\n3. Attend all scheduled follow-up appointments\n4. Report any new symptoms immediately (eye pain, vision changes, redness)\n5. Learn proper medication administration techniques to maximize effectiveness\n\nThe key to a favorable long-term prognosis is early, aggressive intervention and consistent, lifelong monitoring. While angle-closure glaucoma is a serious condition, modern treatment approaches have significantly improved outcomes for patients who receive appropriate care and follow-up.",
    "context": "-----Entities(KG)-----\n\n```json\n[{\"id\": 1, \"entity\": \"Primary Angle-Closure Disease\", \"type\": \"medical_condition\", \"description\": \"Primary Angle-Closure Disease refers to a serious eye condition that can result in acute angle-closure crisis, characterized by various ocular symptoms such as blurred vision and eye pain.<SEP>Primary Angle-Closure Disease refers to a type of glaucoma characterized by the sudden increase in intraocular pressure, leading to symptoms such as blurred vision, eye pain, and possibly visual impairment.<SEP>Primary angle-closure disease is a condition that includes primary angle-closure glaucoma and is characterized by various related entities with specific ICD-10 classifications.\"}, {\"id\": 2, \"entity\": \"Glaucomatous Optic Neuropathy\", \"type\": \"medical_condition\", \"description\": \"Glaucomatous optic neuropathy is a condition that develops when there is damage to the optic nerve, primarily due to elevated intraocular pressure (IOP). This damage can occur rapidly, particularly in patients experiencing a high IOP following an acute angle-closure crisis (AACC), leading to significant visual impairment and the potential for blindness. The diagnosis of glaucomatous optic neuropathy is contingent upon evaluating the optic nerve head (ONH) and the retinal nerve fiber layer (RNFL), which are crucial for identifying the specific structural changes associated with the disease. This condition represents a severe outcome of primary angle-closure disease (PACD) and highlights the importance of monitoring and managing intraocular pressure to prevent optic nerve damage.\"}, {\"id\": 3, \"entity\": \"Acute angle-closure glaucoma\", \"type\": \"medical_condition\", \"description\": \"Acute angle-closure glaucoma is a critical condition that warrants prompt ophthalmology consultation.\"}, {\"id\": 4, \"entity\": \"Primary Angle Closure Disease\", \"type\": \"medical_condition\", \"description\": \"Primary angle closure disease (PACD) is classified into several groups, including primary angle closure suspect, primary angle closure, and primary angle closure glaucoma, each defined by specific criteria related to intraocular pressure and anatomical features.\"}, {\"id\": 5, \"entity\": \"Angle-Closure Glaucoma\", \"type\": \"medical_condition\", \"description\": \"Angle-closure glaucoma is a type of glaucoma that occurs when the drainage canals of the eye become blocked, causing a rapid increase in intraocular pressure.<SEP>Angle-closure glaucoma occurs when the angle between the iris and cornea closes, leading to a rapid increase in eye pressure, necessitating urgent treatment.\"}, {\"id\": 6, \"entity\": \"Primary Open-Angle Glaucoma\", \"type\": \"medical_condition\", \"description\": \"Primary Open-Angle Glaucoma (POAG) is a chronic and progressive eye condition primarily affecting adults. It is characterized by increased intraocular pressure (IOP), which can lead to damage of the optic nerve and potential vision loss. POAG is recognized as a significant public health issue, being the second leading cause of blindness globally, with approximately 76 million individuals affected as of 2020.\\n\\nThe disease involves the bilateral loss of the optic nerve rim and the retinal nerve fiber layer (RNFL), resulting in visual field defects. As the condition progresses, it is associated with acquired atrophy of the optic nerve and the loss of retinal ganglion cells and their axons. The open anterior chamber angle distinguishes POAG from other forms of glaucoma. \\n\\nIf not properly managed, Primary Open-Angle Glaucoma can lead to progressive optic nerve damage and gradual loss of vision. The condition poses serious risks to both vision and overall eye health, making awareness and management crucial.\"}, {\"id\": 7, \"entity\": \"Glaucoma, Open-Angle\", \"type\": \"medical_condition\", \"description\": \"Glaucoma, Open-Angle is the most common form of glaucoma, characterized by a gradual loss of vision and high intraocular pressure without any symptoms in the early stages.\"}, {\"id\": 8, \"entity\": \"Visual Impairment or Blindness\", \"type\": \"clinical_outcome\", \"description\": \"Visual Impairment or Blindness are severe outcomes that may occur if glaucoma is not effectively managed.<SEP>Visual impairment or blindness can result from uncontrolled primary open-angle glaucoma, necessitating the use of rehabilitation services.\"}, {\"id\": 9, \"entity\": \"Glaucoma\", \"type\": \"medical_condition\", \"description\": \"Glaucoma is a chronic and progressive optic neuropathy characterized by damage to the optic nerve, resulting in significant visual field loss and the potential for irreversible blindness. This group of eye conditions is primarily linked to elevated intraocular pressure (IOP), which must be carefully managed to prevent severe impacts on an individual's quality of life. Presently, approximately 3 million people in the United States are affected by glaucoma, with projections suggesting that this number could escalate to around 111.8 million individuals globally by the year 2040, marking it as one of the most common neurodegenerative diseases leading to irreversible blindness.\\n\\nThe condition can complicate cataract surgery due to the risk of elevated postoperative IOP and the reduced effectiveness of previous surgical interventions. Glaucoma is recognized as a risk factor that may contribute to the incidence of suprachoroidal hemorrhage during such procedures. Surgical options to treat glaucoma often involve various techniques, which may be performed in conjunction with cataract surgery.\\n\\nGlaucoma frequently induces psychological challenges, as fears of blindness can adversely impact employment, social interactions, and personal independence. These concerns may increase the likelihood of falls and vehicle accidents, especially among individuals with a family history of glaucoma or those with retinal vein occlusions (RVOs), who have a heightened risk for developing this condition.\\n\\nEffective management of glaucoma requires vigilant monitoring and adherence to prescribed medication regimens, typically consisting of eye drops aimed at maintaining appropriate IOP levels. When IOP remains uncontrolled, medical and surgical interventions may be necessary, with careful considerations for pregnant and lactating patients to ensure safe disease management. Prolonged use of topical corticosteroids can lead to complications such as optic nerve damage and vision loss, emphasizing the importance of regular eye monitoring.\\n\\nMoreover, glaucoma is notably prevalent among patients who have undergone keratoprosthesis placement, with an incidence rate ranging from 72.0% to 86.0%, and a significant percentage (14% to 39.3%) may develop new or progressive cases post-procedure. Current research does not support the efficacy of visual training in improving outcomes for individuals with glaucoma, thereby highlighting the urgent need for effective management strategies.\\n\\nResearch into alternative treatment options, including Ginkgo biloba and compounds like nicotinamide, is ongoing, reflecting the necessity for innovative solutions as glaucoma remains a leading cause of irreversible blindness. Furthermore, the condition often leads to peripheral visual field loss and is more likely to develop in individuals with myopia. Notably, initial studies have indicated that marijuana could potentially lower IOP, suggesting that it may offer a possible avenue for treatment. Overall, early detection through comprehensive eye examinations is crucial, as glaucoma frequently develops asymptomatically, necessitating regular monitoring for timely intervention and more favorable outcomes.<SEP>Glaucoma is a medical condition characterized by increased IOP, which can lead to vision loss, and is noted in some patients after surgery.\"}, {\"id\": 10, \"entity\": \"Primary angle-closure glaucoma\", \"type\": \"medical_condition\", \"description\": \"Primary angle-closure glaucoma has a prevalence of 0.09%–0.26%, with higher rates in Inuit and Asian populations. Risk factors include hyperopia and female gender.\"}, {\"id\": 11, \"entity\": \"Open-Angle Glaucoma\", \"type\": \"medical_condition\", \"description\": \"Open-Angle Glaucoma (POAG) is a significant public health issue, affecting a growing number of people worldwide and recognized as the second leading cause of blindness. It is a common form of glaucoma characterized by a gradual loss of vision due to damage to the optic nerve. This condition is often linked to variations in intraocular pressure (IOP) and corneal thickness (CCT). Open-angle glaucoma requires ongoing management, and treatment is regarded as cost-effective for patients who receive a definitive diagnosis.\"}, {\"id\": 12, \"entity\": \"Primary Open Angle\", \"type\": \"medical_condition\", \"description\": \"Primary open-angle glaucoma is the most common form of glaucoma, where the drainage canals become clogged over time, leading to increased eye pressure and gradual loss of vision.\"}, {\"id\": 13, \"entity\": \"Surgical Management of Angle Closure Glaucoma\", \"type\": \"treatment_method\", \"description\": \"Surgical Management of Angle Closure Glaucoma outlines various surgical interventions for treating this form of glaucoma.<SEP>The Surgical Management of Angle Closure Glaucoma discusses procedures to treat this type of glaucoma.\"}, {\"id\": 14, \"entity\": \"Primary Angle-Closure Glaucoma (PACG)\", \"type\": \"medical_condition\", \"description\": \"PACG is a type of glaucoma that is part of primary angle-closure disease, classified under H40.20X-.<SEP>PACG occurs when PAC progresses with elevated IOP and optic neuropathy, often following episodes of intermittent IOP elevation.<SEP>Primary angle-closure glaucoma (PACG) is characterized by elevated intraocular pressure, peripheral anterior synechiae, and optic neuropathy.\"}, {\"id\": 15, \"entity\": \"Patient Outcome Criteria\", \"type\": \"document_section\", \"description\": \"Patient Outcome Criteria serve as a comprehensive framework for assessing the effectiveness of treatment in ocular health. They outline the necessary evaluations, which include measurements of binocular motor alignment, sensory status, visual acuity, and patient-reported quality of life. The criteria are designed to set specific objectives for managing various ocular conditions, prioritizing the reduction of symptoms and the preservation of visual function.\\n\\nFor conditions such as dry eye, the primary focus of the criteria is on alleviating symptoms while maintaining visual acuity. In cases of conjunctivitis, the goals extend to eliminating symptoms, restoring visual function, detecting underlying diseases, preventing damage to the ocular surface, and controlling the spread of infection. The overarching goals include managing neovascular complications, improving visual function, preserving quality of life, and minimizing risks of future acute angioid choroidal complications (AACC).\\n\\nThe Patient Outcome Criteria also specify significant treatment outcomes for other conditions like posterior vitreous detachment (PVD) and retinal detachment (RRD), emphasizing the prevention of visual loss and the maintenance of quality of life. For primary open-angle glaucoma (POAG), the criteria ensure effective management by focusing on visual function and the patient's quality of life. In the context of age-related macular degeneration (AMD), there is an emphasis on reversing or minimizing visual loss while enhancing visual capabilities.\\n\\nAdditionally, the criteria address other specific conditions such as superior oblique palsy, skew deviation, and strabismus, with focused objectives that prioritize symptom management. In superior oblique palsy, the aim is to restore ocular alignment and improve binocular vision, while for skew deviation, the criteria emphasize alleviating visual symptoms and reducing diplopia. In strabismus, the focus remains on enhancing quality of life by reducing diplopia and improving ocular alignment.\\n\\nOverall, the Patient Outcome Criteria provide a structured approach for evaluating treatment effectiveness, ensuring that various metrics aimed at assessing improvements in visual function, quality of life, risk reduction, and chronic disease management are taken into account, all while considering the individual needs of patients.\"}, {\"id\": 16, \"entity\": \"primary open-angle glaucoma (POAG)\", \"type\": \"medical_condition\", \"description\": \"Primary open-angle glaucoma (POAG) is an eye condition characterized by elevated intraocular pressure and specific optic nerve damage.<SEP>Primary open-angle glaucoma is a chronic eye condition that may lead to visual field loss and is often asymptomatic until late stages.\"}, {\"id\": 17, \"entity\": \"Acute Angle-Closure Glaucoma\", \"type\": \"medical_condition\", \"description\": \"Acute angle-closure glaucoma is a complication that can occur during EK procedures, causing sudden eye pressure and vision issues.<SEP>Acute angle-closure glaucoma is classified under ICD-10 code H40.21- and is a serious eye condition.<SEP>Acute angle-closure glaucoma is a serious eye condition that can occur after pharmacologic dilation, characterized by a rapid rise in intraocular pressure.\"}, {\"id\": 18, \"entity\": \"Patients with Ocular Hypertension\", \"type\": \"patient_population\", \"description\": \"Patients with ocular hypertension are individuals identified by elevated intraocular pressure, whose treatment considerations vary based on risk factors and life expectancy.\"}, {\"id\": 19, \"entity\": \"Vision Loss\", \"type\": \"clinical_outcome\", \"description\": \"Vision loss encompasses a decline in visual acuity that can significantly affect an individual’s daily activities, safety, and overall quality of life. It can manifest as partial or complete loss of vision and is associated with various ocular issues and complications. Causes of vision loss include degenerative changes related to high myopia, untreated conjunctivitis leading to severe complications like corneal ulceration or keratitis, and retinal vein occlusions linked to ischemia or edema. Furthermore, surgical procedures such as vitrectomy carry risks, including potential retinal damage, while chronic conditions like untreated blepharitis threaten eye health. The improper use of cosmetic contact lenses also poses a risk, potentially resulting in severe reductions in visual ability. \\n\\nUntreated glaucoma is another major concern, as it can lead to blindness if not managed appropriately. Overall, vision loss represents a serious condition that requires timely medical intervention and rehabilitative services to help patients cope with the changes in their vision and adapt their daily lives accordingly. It highlights the necessity for prompt diagnosis and treatment to preserve eye health and functioning, emphasizing the importance of support from loved ones in navigating the challenges posed by this impairment.<SEP>Vision loss is a potential outcome in patients with Thyroid Eye Disease, particularly due to conditions like optic neuropathy.\"}, {\"id\": 20, \"entity\": \"Primary Open-Angle Glaucoma (POAG)\", \"type\": \"medical_condition\", \"description\": \"Primary Open-Angle Glaucoma (POAG) is a prevalent and chronic eye condition recognized as the most common form of glaucoma. It typically develops in glaucoma suspects and requires ongoing monitoring and management due to the potential for progressive damage to the optic nerve and subsequent vision loss if left untreated. POAG is characterized by increased intraocular pressure (IOP) and open anterior chamber angles, as well as specific clinical findings, including the need for meticulous documentation of the appearance of the optic nerve and retinal nerve fiber layer (RNFL).\\n\\nNumerous clinical trials have been conducted to analyze treatment outcomes and progression rates associated with POAG. Management strategies often include various therapeutic approaches, such as laser trabeculoplasty. Research has identified several risk factors influencing the condition, including thinner central corneal thickness, which underscores the multifactorial nature of POAG. Given the gradual loss of vision associated with untreated high IOP, timely diagnosis and management are essential for preserving visual function in affected individuals.<SEP>Primary open-angle glaucoma is a common form of glaucoma that can be managed through various surgical and medical treatments.\"}, {\"id\": 21, \"entity\": \"Table 7\", \"type\": \"document_section\", \"description\": \"Table 7 summarizes consensus-based guidelines for the follow-up evaluation of glaucoma management outcomes.\"}, {\"id\": 22, \"entity\": \"Primary Angle Closure OTA\", \"type\": \"medical_condition\", \"description\": \"Primary Angle Closure OTA refers to a type of glaucoma where the drainage angle of the eye is blocked, leading to increased pressure.\"}]\n```\n\n-----Relationships(KG)-----\n\n```json\n[{\"id\": 1, \"entity1\": \"Angle-Closure Glaucoma\", \"entity2\": \"Glaucoma\", \"description\": \"Angle-closure glaucoma presents a more acute risk that requires immediate medical intervention to prevent vision loss.\"}, {\"id\": 2, \"entity1\": \"Glaucomatous Optic Neuropathy\", \"entity2\": \"Primary Angle Closure Disease\", \"description\": \"Glaucomatous optic neuropathy can result from untreated primary angle closure disease, illustrating a severe consequence of the condition.\"}, {\"id\": 3, \"entity1\": \"Glaucoma\", \"entity2\": \"Primary Open Angle\", \"description\": \"Primary open-angle glaucoma is a specific type of glaucoma that affects the drainage of fluid in the eye, contributing to increased intraocular pressure.\"}, {\"id\": 4, \"entity1\": \"Primary Open-Angle Glaucoma\", \"entity2\": \"Visual Impairment or Blindness\", \"description\": \"Visual Impairment or Blindness may result from untreated Primary Open-Angle Glaucoma, making its management crucial to prevention.\\\"|>\\\"outcome, disease impact\"}, {\"id\": 5, \"entity1\": \"Initial Physical Exam\", \"entity2\": \"Primary Angle-Closure Disease\", \"description\": \"Initial Physical Exam includes key examination findings critical for confirming Primary Angle-Closure Disease.\"}, {\"id\": 6, \"entity1\": \"Glaucoma\", \"entity2\": \"Open-Angle Glaucoma\", \"description\": \"Open-angle glaucoma is a prevalent form of glaucoma leading to gradual vision loss, requiring long-term management.\"}, {\"id\": 7, \"entity1\": \"Intraocular Pressure (IOP)\", \"entity2\": \"Primary Angle-Closure Glaucoma (PACG)\", \"description\": \"Elevated IOP and the presence of PAS indicate a transition from PAC to PACG with potential optic nerve damage.\"}, {\"id\": 8, \"entity1\": \"Glaucoma\", \"entity2\": \"Surgical Management of Angle Closure Glaucoma\", \"description\": \"The management of Angle Closure Glaucoma through surgical techniques is discussed in the context of treating glaucoma.\"}, {\"id\": 9, \"entity1\": \"Patient Education\", \"entity2\": \"Primary Angle-Closure Disease\", \"description\": \"Patient Education aims to inform individuals about the risks and symptoms of Primary Angle-Closure Disease and promotes timely consultation.\"}, {\"id\": 10, \"entity1\": \"Patient Outcome Criteria\", \"entity2\": \"Primary Open-Angle Glaucoma\", \"description\": \"The criteria for successful patient outcomes focus on managing Primary Open-Angle Glaucoma effectively in terms of visual function and quality of life.\"}, {\"id\": 11, \"entity1\": \"Angle-Closure Glaucoma\", \"entity2\": \"Primary Open-Angle Glaucoma\", \"description\": \"Primary open-angle glaucoma and angle-closure glaucoma are both classifications of the disease known as glaucoma, affecting vision due to optic nerve damage.\"}, {\"id\": 12, \"entity1\": \"Initial Exam History\", \"entity2\": \"Primary Angle-Closure Disease\", \"description\": \"Initial Exam History provides essential information related to the diagnosis of Primary Angle-Closure Disease.<SEP>The Initial Exam History provides foundational information necessary to evaluate and diagnose Primary Angle-Closure Disease.\"}, {\"id\": 13, \"entity1\": \"Open-Angle Glaucoma\", \"entity2\": \"Patients with Ocular Hypertension\", \"description\": \"Patients with ocular hypertension are at risk for developing open-angle glaucoma, necessitating careful management and treatment decisions.\"}, {\"id\": 14, \"entity1\": \"Gonioscopy\", \"entity2\": \"Primary Angle-Closure Disease\", \"description\": \"Gonioscopy is performed to assess the angle of the anterior chamber, crucial in diagnosing Primary Angle-Closure Disease.\"}, {\"id\": 15, \"entity1\": \"Glaucoma\", \"entity2\": \"Vision Loss\", \"description\": \"Untreated glaucoma can lead to vision loss, emphasizing the importance of effective treatment strategies.\"}, {\"id\": 16, \"entity1\": \"Ocular History\", \"entity2\": \"Primary Angle-Closure Disease\", \"description\": \"Ocular history is integral in identifying symptoms related to Primary Angle-Closure Disease.\"}, {\"id\": 17, \"entity1\": \"Primary Open-Angle Glaucoma (POAG)\", \"entity2\": \"Table 7\", \"description\": \"Table 7 provides guidelines for the follow-up of patients with primary open-angle glaucoma, addressing IOP and progression monitoring.\"}, {\"id\": 18, \"entity1\": \"Laser Iridotomy\", \"entity2\": \"Primary Angle-Closure Disease\", \"description\": \"Laser iridotomy is a treatment method indicated for managing acute angle-closure crisis in Primary Angle-Closure Disease cases.\"}, {\"id\": 19, \"entity1\": \"Primary Angle Closure OTA\", \"entity2\": \"Surgical Management of Angle Closure Glaucoma\", \"description\": \"Surgical Management of Angle Closure Glaucoma directly pertains to treatment options available for Primary Angle Closure OTA.\"}, {\"id\": 20, \"entity1\": \"Key Recommendations for Care\", \"entity2\": \"primary open-angle glaucoma (POAG)\", \"description\": \"Key recommendations for care directly involve treatment strategies for managing conditions like primary open-angle glaucoma (POAG).\"}, {\"id\": 21, \"entity1\": \"Fundus Examination\", \"entity2\": \"Glaucomatous Optic Neuropathy\", \"description\": \"\\\"Fundus examination is utilized to search for other abnormalities that may indicate glaucomatous changes affecting the optic nerve.\\\")\"}, {\"id\": 22, \"entity1\": \"myopia\", \"entity2\": \"primary open-angle glaucoma (POAG)\", \"description\": \"Myopia has been identified as a risk factor for primary open-angle glaucoma (POAG), suggesting a link between refractive error and eye pressure issues.\"}, {\"id\": 23, \"entity1\": \"Glaucomatous Optic Neuropathy\", \"entity2\": \"Optic Nerve Head (ONH)\", \"description\": \"\\\"The ONH examination provides crucial information for assessing glaucomatous optic neuropathy.\\\")<SEP>Changes in the optic nerve head are critical indicators of glaucomatous optic neuropathy as observed during examinations.\"}, {\"id\": 24, \"entity1\": \"Glaucoma, Open-Angle\", \"entity2\": \"Intraocular Pressure\", \"description\": \"Open-Angle glaucoma is specifically characterized by increased intraocular pressure as a key indicator for diagnosis.\"}, {\"id\": 25, \"entity1\": \"Acute Angle-Closure Crisis (AACC)\", \"entity2\": \"Primary Angle-Closure Glaucoma (PACG)\", \"description\": \"AACC can lead to PACG if not treated effectively, showing the progression of complications in angle-closure diseases.\"}, {\"id\": 26, \"entity1\": \"IOP Measurement\", \"entity2\": \"Primary Angle-Closure Disease\", \"description\": \"IOP measurements are essential in evaluating the severity and management of Primary Angle-Closure Disease.\"}, {\"id\": 27, \"entity1\": \"Glaucomatous Optic Neuropathy\", \"entity2\": \"Retinal Nerve Fiber Layer (RNFL)\", \"description\": \"\\\"The RNFL is examined for signs of thinning, which is critical in diagnosing glaucomatous optic neuropathy.\\\")<SEP>Thinning of the retinal nerve fiber layer is another structural change indicative of glaucomatous optic neuropathy.\"}, {\"id\": 28, \"entity1\": \"primary open-angle glaucoma (POAG)\", \"entity2\": \"systemic arterial hypertension\", \"description\": \"Systemic arterial hypertension has been noted in studies as being associated with primary open-angle glaucoma, implying a relationship between them.\"}, {\"id\": 29, \"entity1\": \"intraocular pressure (IOP)\", \"entity2\": \"primary open-angle glaucoma (POAG)\", \"description\": \"Intraocular pressure (IOP) is a significant factor in the diagnosis and management of primary open-angle glaucoma (POAG).\"}, {\"id\": 30, \"entity1\": \"Primary Angle-Closure Disease\", \"entity2\": \"Primary Angle-Closure Glaucoma (PACG)\", \"description\": \"Primary angle-closure glaucoma is a subtype included under the broader category of primary angle-closure disease.\"}, {\"id\": 31, \"entity1\": \"African race\", \"entity2\": \"primary open-angle glaucoma (POAG)\", \"description\": \"African race is a significant risk factor for developing primary open-angle glaucoma (POAG), reflecting susceptibility linked to ethnicity.\"}, {\"id\": 32, \"entity1\": \"IOP measurement\", \"entity2\": \"primary open-angle glaucoma (POAG)\", \"description\": \"IOP measurement is a method used to assess primary open-angle glaucoma but has limitations in population screening.\"}, {\"id\": 33, \"entity1\": \"Latino/Hispanic ethnicity\", \"entity2\": \"primary open-angle glaucoma (POAG)\", \"description\": \"Latino/Hispanic ethnicity is associated with a higher risk of developing primary open-angle glaucoma (POAG), indicating demographic vulnerabilities.\"}, {\"id\": 34, \"entity1\": \"Management Plan for Patients in Whom Iridotomy is Indicated\", \"entity2\": \"Primary Angle-Closure Disease\", \"description\": \"The Management Plan outlines the treatment strategies for managing Primary Angle-Closure Disease.\"}, {\"id\": 35, \"entity1\": \"lowering pressure\", \"entity2\": \"primary open-angle glaucoma (POAG)\", \"description\": \"Lowering intraocular pressure is an essential treatment method for managing primary open-angle glaucoma (POAG).\"}, {\"id\": 36, \"entity1\": \"Glaucomatous Optic Neuropathy\", \"entity2\": \"Ocular Features\", \"description\": \"Ocular features such as optic nerve changes are critical indicators of glaucomatous optic neuropathy, providing essential information for diagnosis.\"}, {\"id\": 37, \"entity1\": \"Primary Angle-Closure Disease (PACD)\", \"entity2\": \"Primary Angle-Closure Glaucoma (PACG)\", \"description\": \"PACG represents a more severe form of PACD involving optic nerve damage due to elevated pressure.\"}, {\"id\": 38, \"entity1\": \"AGE\", \"entity2\": \"primary open-angle glaucoma (POAG)\", \"description\": \"Older age is a major risk factor for primary open-angle glaucoma (POAG), emphasizing the importance of age-related eye health monitoring.\"}, {\"id\": 39, \"entity1\": \"Corneal Swelling\", \"entity2\": \"Primary Angle-Closure Disease\", \"description\": \"Corneal swelling is a clinical finding that indicates an acute attack of Primary Angle-Closure Disease.\"}, {\"id\": 40, \"entity1\": \"primary open-angle glaucoma (POAG)\", \"entity2\": \"visual field defects\", \"description\": \"Visual field defects are characteristic outcomes of primary open-angle glaucoma (POAG), reflecting disease progression.\"}, {\"id\": 41, \"entity1\": \"primary open-angle glaucoma (POAG)\", \"entity2\": \"thin central cornea\", \"description\": \"A thin central cornea is a contributing risk factor for primary open-angle glaucoma (POAG), affecting ocular biomechanics.\"}, {\"id\": 42, \"entity1\": \"ONH and RNFL assessment\", \"entity2\": \"primary open-angle glaucoma (POAG)\", \"description\": \"Assessing ONH and RNFL is a diagnostic method relevant to the evaluation of primary open-angle glaucoma.\"}, {\"id\": 43, \"entity1\": \"primary open-angle glaucoma (POAG)\", \"entity2\": \"visual field evaluation\", \"description\": \"Visual field evaluation is utilized as a diagnostic tool for identifying potential cases of primary open-angle glaucoma.\"}, {\"id\": 44, \"entity1\": \"Computer-based imaging\", \"entity2\": \"primary open-angle glaucoma (POAG)\", \"description\": \"Computer-based imaging is used in the evaluation and diagnosis of primary open-angle glaucoma (POAG).\"}, {\"id\": 45, \"entity1\": \"primary open-angle glaucoma (POAG)\", \"entity2\": \"type 2 diabetes mellitus\", \"description\": \"Type 2 diabetes mellitus is a recognized risk factor for primary open-angle glaucoma (POAG), linking metabolic health to eye health.\"}, {\"id\": 46, \"entity1\": \"Acute Angle-Closure Glaucoma (AACC)\", \"entity2\": \"Primary Angle-Closure Disease\", \"description\": \"Acute angle-closure glaucoma represents an acute manifestation of primary angle-closure disease.\"}, {\"id\": 47, \"entity1\": \"Primary Angle-Closure Disease\", \"entity2\": \"Symptoms of AACC\", \"description\": \"Symptoms of AACC help in recognizing acute episodes related to Primary Angle-Closure Disease and facilitate timely medical intervention.\"}, {\"id\": 48, \"entity1\": \"Glaucomatous Optic Neuropathy\", \"entity2\": \"Neuroretinal Rim\", \"description\": \"\\\"The width and characteristics of the neuroretinal rim are important indicators of glaucomatous optic neuropathy status.\\\")\"}, {\"id\": 49, \"entity1\": \"Glaucomatous Optic Neuropathy\", \"entity2\": \"Optic Disc Hemorrhages\", \"description\": \"\\\"Optic disc hemorrhages can signal focal damage associated with glaucomatous optic neuropathy.\\\")\"}, {\"id\": 50, \"entity1\": \"Glaucomatous Optic Neuropathy\", \"entity2\": \"High IOP\", \"description\": \"High IOP is a contributing factor that leads to the development of glaucomatous optic neuropathy in the presence of AACC.\"}, {\"id\": 51, \"entity1\": \"Glaucomatous Optic Neuropathy\", \"entity2\": \"Optic Nerve Head and Retinal Nerve Fiber Layer Examination\", \"description\": \"The examination specifically assesses for signs that indicate glaucomatous optic neuropathy, highlighting their connection and relevance.\"}, {\"id\": 52, \"entity1\": \"Glaucomatous Optic Neuropathy\", \"entity2\": \"Standard Automated Perimetry (SAP)\", \"description\": \"Standard automated perimetry is used to detect functional defects in glaucoma, complementing structural evaluations for glaucomatous optic neuropathy.\"}, {\"id\": 53, \"entity1\": \"Acute Angle-Closure Glaucoma\", \"entity2\": \"EK\", \"description\": \"Acute angle-closure glaucoma is a possible complication associated with EK surgeries, highlighting the risks involved.\"}, {\"id\": 54, \"entity1\": \"Medical Condition Risk Factors\", \"entity2\": \"Primary angle-closure glaucoma\", \"description\": \"Primary angle-closure glaucoma's prevalence is influenced by demographic factors such as ethnicity and gender.\"}, {\"id\": 55, \"entity1\": \"Individuals of Asian descent\", \"entity2\": \"Primary angle-closure glaucoma\", \"description\": \"Individuals of Asian descent are at higher risk for primary angle-closure glaucoma, showcasing specific demographic susceptibility.\"}, {\"id\": 56, \"entity1\": \"Iridotrabecular Contact (ITC)\", \"entity2\": \"Primary Angle-Closure Glaucoma (PACG)\", \"description\": \"Significant ITC is tied to the risk of developing PACG and indicates a severe form of angle-closure disease.\"}, {\"id\": 57, \"entity1\": \"Acute Angle-Closure Glaucoma\", \"entity2\": \"Pharmacologic Mydriasis\", \"description\": \"The risk of acute angle-closure glaucoma can arise from pharmacologic mydriasis, raising concerns among clinicians about its safety.\"}, {\"id\": 58, \"entity1\": \"Acute Angle-Closure Glaucoma\", \"entity2\": \"Laser Peripheral Iridotomy (LPI)\", \"description\": \"Laser Peripheral Iridotomy is a preventive measure against acute angle-closure glaucoma in at-risk patients subjected to dilation.\"}, {\"id\": 59, \"entity1\": \"Acute Angle-Closure Glaucoma\", \"entity2\": \"Symptoms of Acute Angle Closure\", \"description\": \"Symptoms such as eye pain and blurred vision are indicative of an acute angle-closure glaucoma episode, highlighting the condition's seriousness.\"}]\n```\n\n-----Document Chunks(DC)-----\n\n```json\n[{\"id\": 1, \"content\": \"## Information Statement on the Safety of Pharmacologic Mydriasis for Diabetic Retinopathy Screening\\nWhile the gold standard for diabetic retinopathy (DR) screening is a dilated funduscopic examination by an ophthalmologist, alternative methods such as telemedicine-based programs and artificial intelligence (AI)-based programs have allowed the expansion of DR screening programs to primary care and rural settings.¹ Telemedicine and AI screening involves color fundus photography. The images are interpreted by clinicians or trained readers, in the case of telemedicine, or at the point of care by a United States Food and Drug Administration-approved AI system.\\nThe diagnostic yield of color fundus photography-based DR screening is greatly improved with the use of pharmacologic mydriasis. For example, in a DR screening study, the use of tropicamide 1% reduced the proportion of ungradable images from 26% to 5%.² However, primary care clinicians' fear of the risk of acute angle closure may limit the use of pharmacologic dilation and thus limit the yield of screening examinations.\\nThe actual risk of acute angle-closure glaucoma after pharmacologic pupillary dilation is very low. Among more than 4800 participants in the cross-sectional Baltimore Eye Study who were dilated with tropicamide 1% and phenylephrine 2.5%, there were no reported cases of acute angle-closure glaucoma.³ Thirty-eight participants who were referred for a definitive eye examination were judged by an ophthalmologist to have anterior eye anatomy at risk for angle closure (\\\"occludable angles\\\").³ Of these, 28 participants were dilated with tropicamide 0.5%, and none developed acute angle-closure glaucoma.³ The remaining 10 participants underwent laser peripheral iridotomy surgery (LPI) prior to dilation, but it is unknown whether they would have developed acute angle-closure glaucoma without this procedure.³ The combination of a shallow anterior chamber by penlight examination and a history of glaucoma were the most effective combination of risk factors for predicting a potentially occludable angle.³\\nIn a systematic review of approximately 600,000 people who underwent pharmacologic mydriasis for screening eye examinations, acute angle-closure glaucoma occurred in 33 individuals (0.006%), all of whom had received long-acting (atropine or homatropine) or combination (phenylephrine plus tropicamide) dilating agents.⁴ Among nearly 4000 patients who received tropicamide only, there were no cases of acute angle-closure glaucoma.⁴ In addition, there were no documented cases of acute angle-closure glaucoma among more than 1000 dilated patients with a history of chronic open-angle glaucoma.⁴\\nSimilarly, in a retrospective review of more than 95,000 patients in the Northern Ireland Diabetic Retinopathy Screening Program, there were only 3 reported cases of angle closure among individuals who underwent dilation with tropicamide 1%.⁵ The overall risk of angle closure was 1 in 31,755 patients, with an annual incidence of 0.75 cases per year.⁵ For comparison, the overall annual risk of acute angle-closure glaucoma in the general population without dilation has been estimated at 2.2 to 4.1 cases per 100,000 in European populations and 12.2 per 100,000 in Singapore.⁶⁻⁹\\nEven among populations at greater risk for angle closure such as Asian individuals, the risk of acute angle-closure glaucoma after pharmacologic dilation is very low.¹⁰ For example, a randomized study...\\n## Controlled Trial and Pharmacologic Dilation\\nA controlled trial in China studied the risk of acute angle-closure attacks after pharmacologic dilation in nearly 900 individuals who had been diagnosed as bilateral primary angle-closure suspect. Participants received LPI in one eye and no treatment in the other, and both eyes were dilated 6 times with phenylephrine 5% and tropicamide 0.5% over 72 months of follow-up. Over this time period, there were only 2 cases of post-dilation acute angle-closure attacks in eyes that did not receive LPI. The overall risk of acute angle-closure attack in untreated eyes was 1 in 1587 dilations (0.063%).\\nSimilarly, in a cross-sectional study in China of patients with diabetes mellitus dilated with phenylephrine 0.5% and tropicamide 0.5%, only one of nearly 2300 patients developed acute angle closure. In another observational case series in more than 1900 patients with diabetes in China, dilation with either phenylephrine 2.5% plus tropicamide 1% or tropicamide 1% alone resulted in no cases of acute angle closure.\\nTaken as a whole, the above data support that pharmacologic dilation with tropicamide 1% is safe, and the risk of acute angle-closure glaucoma is very low. Therefore, routine dilation with tropicamide can be implemented in DR screening programs to improve the diagnostic yield of fundus photography. However, primary care settings should also have ophthalmologist referral networks available in case of rare adverse events with dilation. Symptoms of acute angle closure can include unilateral or bilateral eye pain, headache, nausea, vomiting, blurred vision, and seeing halos around lights. In the event that these symptoms develop within hours after pharmacologic pupillary dilation, referral to an ophthalmologist or an emergency physician is warranted.\", \"file_path\": \"medical_guide_markdown/Dilation Information Statement - 2025.md\"}, {\"id\": 2, \"content\": \"## Primary Open-Angle Glaucoma Suspect (Initial and Follow-up Evaluation)\\n### Initial Exam History (Key elements)\\n- Ocular history (e.g., refractive error, trauma, prior ocular surgery)\\n- Race/ethnicity\\n- Family history\\n- Systemic history\\n- Review of pertinent records\\n- Current and prior ocular and nonocular medications\\n- Prior cataract surgery, LASIK and/or incisional surgery\\n### Initial Physical Exam (Key elements)\\n- Visual acuity measurement\\n- Pupil examination\\n- Confrontation visual field\\n- Slit-lamp biomicroscopy\\n- IOP measurement\\n- Gonioscopy\\n- Optic nerve head (ONH) and retinal nerve fiber layer (RNFL) examination\\n- Fundus examination\\n### Diagnostic Testing (Key elements)\\n- Central corneal thickness (CCT) measurement\\n- Visual field evaluation. If visual field glaucomatous damage is newly detected in a glaucoma suspect patient, it is best to repeat testing.\\n- ONH, RNFL, and macular imaging. Clinicians should include all perimetric and other structural information in addition to digital imaging technology when formulating patient management decisions.\\n### Management Plan for Patients in Whom Therapy is Indicated\\n- The goal of treatment is to monitor or lower IOP through treatment if an eye is likely to progress to POAG; monitor for structural changes in optic disc and retina; and monitor for functional changes of the optic nerve assessing the visual field.\\n- The decision to treat a glaucoma suspect patient may arise in various settings (see POAG Suspect PPP for detailed considerations).\\n- Target IOP is an estimate and must be individualized and/or adjusted during the course of the disease.\\n- Medical therapy is presently the most common initial intervention to lower IOP (see Table 2 of the POAG Suspect PPP for an overview of options available); consider balance between side effects and effectiveness in choosing a regimen of maximal effectiveness and tolerance to achieve the desired IOP reduction for each patient.\\n- If a medical therapy fails to reduce IOP sufficiently, then either switching to an alternative medication as monotherapy or adding additional medication is appropriate until the desired IOP level is attained.\\n### Follow-up Exam History\\n- Interval ocular history\\n- Interval systemic medical and medication history\\n- Side effects of ocular medications if the patient is being treated\\n- Review of pertinent medication use if the patient is being treated, including the time of the last administration\\n### Follow-up Physical Exam\\n- Visual acuity measurement\\n- Slit-lamp biomicroscopy\\n- IOP measurement\\n- Gonioscopy is indicated when there is a suspicion of development of an angle-closure component, anterior chamber shallowing, anterior chamber angle abnormalities, or unexplained change in IOP\\n### Adjustment of Therapy\\n- Target IOP is not achieved and the benefits of a change in therapy outweigh the risks for the patient\\n- The patient is intolerant of the prescribed medical regimen\\n- The patient does not adhere to the prescribed medical regimen due to costs or other factors\\n- New systemic conditions or treatments develop that could be a contraindication to the current glaucoma therapy\\n- The patient under treatment has been stable for a prolonged period without progression to POAG, in which case cautious withdrawal of therapy may be considered\\n- The patient has converted to POAG (see Primary Open-Angle Glaucoma PPP)\\n## Primary Open-Angle Glaucoma Suspect (Initial and Follow-up Evaluation) (continued)\\n### Patient Education\\n- Discuss number and severity of risk factors, prognosis, life expectancy, management plan, and likelihood that therapy, once started, can be continued long term.\\n- Educate about their condition and its potential to lead to glaucoma, the status of their condition, the rationale and goals of intervention, and relative benefits and risks of alternative interventions.\\n- Educate about eyelid closure or nasolacrimal occlusion to reduce systemic absorption after medication instillation.\\n- Encourage patients to alert their ophthalmologist to physical or emotional changes that occur when taking glaucoma medications.\\n- Patients with substantial visual impairment or blindness can be referred for and encouraged to use appropriate vision rehabilitation and social services.\", \"file_path\": \"medical_guide_markdown/PPP Summary Benchmarks.24.glaucoma.md\"}, {\"id\": 3, \"content\": \"## Primary Open-Angle Glaucoma Suspect (Initial and Follow-up Evaluation)\\n### Initial Exam History (Key elements)\\n- Ocular history (e.g., refractive error, trauma, prior ocular surgery)\\n- Race/ethnicity\\n- Family history\\n- Systemic history\\n- Review of pertinent records\\n- Current and prior ocular and nonocular medications\\n- Prior cataract surgery, LASIK and/or incisional surgery\\n### Initial Physical Exam (Key elements)\\n- Visual acuity measurement\\n- Pupil examination\\n- Confrontation visual field\\n- Slit-lamp biomicroscopy\\n- IOP measurement\\n- Gonioscopy\\n- Optic nerve head (ONH) and retinal nerve fiber layer (RNFL) examination\\n- Fundus examination\\n### Diagnostic Testing (Key elements)\\n- Central corneal thickness (CCT) measurement\\n- Visual field evaluation. If visual field glaucomatous damage is newly detected in a glaucoma suspect patient, it is best to repeat testing.\\n- ONH, RNFL, and macular imaging. Clinicians should include all perimetric and other structural information in addition to digital imaging technology when formulating patient management decisions.\\n### Management Plan for Patients in Whom Therapy is Indicated\\n- The goal of treatment is to monitor or lower IOP through treatment if an eye is likely to progress to POAG; monitor for structural changes in optic disc and retina; and monitor for functional changes of the optic nerve assessing the visual field.\\n- The decision to treat a glaucoma suspect patient may arise in various settings (see POAG Suspect PPP for detailed considerations).\\n- Target IOP is an estimate and must be individualized and/or adjusted during the course of the disease.\\n- Medical therapy is presently the most common initial intervention to lower IOP (see Table 2 of the POAG Suspect PPP for an overview of options available); consider balance between side effects and effectiveness in choosing a regimen of maximal effectiveness and tolerance to achieve the desired IOP reduction for each patient.\\n- If a medical therapy fails to reduce IOP sufficiently, then either switching to an alternative medication as monotherapy or adding additional medication is appropriate until the desired IOP level is attained.\\n### Follow-up Exam History\\n- Interval ocular history\\n- Interval systemic medical and medication history\\n- Side effects of ocular medications if the patient is being treated\\n- Review of pertinent medication use if the patient is being treated, including the time of the last administration\\n### Follow-up Physical Exam\\n- Visual acuity measurement\\n- Slit-lamp biomicroscopy\\n- IOP measurement\\n- Gonioscopy is indicated when there is a suspicion of development of an angle-closure component, anterior chamber shallowing, anterior chamber angle abnormalities, or unexplained change in IOP\\n### Adjustment of Therapy\\n- Target IOP is not achieved and the benefits of a change in therapy outweigh the risks for the patient\\n- The patient is intolerant of the prescribed medical regimen\\n- The patient does not adhere to the prescribed medical regimen due to costs or other factors\\n- New systemic conditions or treatments develop that could be a contraindication to the current glaucoma therapy\\n- The patient under treatment has been stable for a prolonged period without progression to POAG, in which case cautious withdrawal of therapy may be considered\\n- The patient has converted to POAG (see Primary Open-Angle Glaucoma PPP)\\n## Primary Open-Angle Glaucoma Suspect (Initial and Follow-up Evaluation) (continued)\\n### Patient Education\\n- Discuss number and severity of risk factors, prognosis, life expectancy, management plan, and likelihood that therapy, once started, can be continued long term\\n- Educate about their condition and its potential to lead to glaucoma, the status of their condition, the rationale and goals of intervention, and relative benefits and risks of alternative interventions\\n- Educate about eyelid closure or nasolacrimal occlusion to reduce systemic absorption after medication instillation\\n- Encourage patients to alert their ophthalmologist to physical or emotional changes that occur when taking glaucoma medications\\n- Patients with substantial visual impairment or blindness can be referred for and encouraged to use appropriate vision rehabilitation and social services\", \"file_path\": \"medical_guide_markdown/PPP Summary Benchmarks.24.full set.md\"}]\n```\n\n",
    "QuestionID": "1",
    "llm_name": "deepseek-chat",
    "Question": "What is the long-term prognosis for my left eye primary acute angle-closure glaucoma?",
    "clinical_data": {
        "Age": 79.0,
        "Gender": "Female",
        "AdmissionDate": "2024-06-30T00:00:00",
        "DischargeDate": "2024-07-05T00:00:00",
        "AdmissionDiagnosis": "1. Left eye primary acute angle-closure glaucoma; 2. Left eye senile cataract",
        "DischargeDiagnosis": "1. Left eye primary acute angle-closure glaucoma; 2. Left eye senile cataract",
        "ClinicalHistory": "Chief Complaint: Sudden onset of distending pain and blurred vision in the left eye for 4 days.\nHistory of Present Illness: Four days ago, the patient experienced sudden onset of distending pain in the left eye without obvious precipitating factors, accompanied by a rapid decrease in vision. Both distant and near vision were unclear, accompanied by irritative symptoms such as eye redness, photophobia, and tearing, as well as ipsilateral headache and nausea. Denied history of ocular trauma. Due to persistent unremitting symptoms, the patient came to our hospital today for treatment. After relevant examinations in the outpatient clinic, the patient was admitted with a provisional diagnosis of \"1. Primary acute angle-closure glaucoma in the left eye; 2. Bilateral pseudophakia.\" During the course of the illness, there was no fever or cough. Appetite and sleep were poor, but bowel movements and urination were normal.\nPast Medical History and Surgical/Trauma History: General condition: Generally healthy. Denied history of chronic diseases such as diabetes and coronary heart disease; denied history of blood transfusion and trauma. Denied history of infectious diseases such as hepatitis, tuberculosis, bacillary dysentery, and typhoid fever. Immunizations were completed on schedule. Denied known allergies to sulfonamides, streptomycin, gentamicin, penicillin, cephalosporins, other medications, or food.\nOphthalmic Examination: Vod 0.4 Vos 0.1. IOP OD Tn OS T+2. Right eye: conjunctiva without hyperemia, cornea clear, peripheral anterior chamber shallow, aqueous humor clear, pupil round, diameter approximately 3mm, light reflex (+), lens turbid, fundus visible with retina attached, no obvious hemorrhage or exudation seen. Left eye: conjunctival mixed hyperemia (++), corneal opacity and edema, subepithelial bullae, KP (-), anterior chamber shallow, peripheral anterior chamber <1/3 CT, aqueous flare (+), pupil round, diameter approximately 4mm, light reflex (+), lens turbid, fundus view obscured.",
        "DifferentialDiagnosis": "1. Acute iridocyclitis: Sudden onset of eye redness, eye pain, varying degrees of vision loss, intraocular pressure often not elevated, significant anterior chamber inflammatory reaction, pupil constricted and irregular in shape.\n2. Glaucomatocyclitic crisis: Patients are mostly young and middle-aged adults, intraocular pressure sharply increases, local irritation symptoms are relatively mild, anterior chamber is not shallow, angle is open, with mutton-fat keratic precipitates on the posterior cornea."
    },
    "llm_answer_type": "LLM_LightRAG_Hybrid_Distillation_Response",
    "temperature": 0
}